Table 3.
Distribution of baseline SARS-CoV-2 clades (variants) in the modified intention-to-treat population
| Molnupiravir | Placebo | |||
|---|---|---|---|---|
| N | (%)a | N | (%)a | |
| Modified intention-to-treat population | 709 | – | 699 | – |
| Participants with evaluable sequence data | 534 | (75.3) | 529 | (75.5) |
| 19B (Washington State) | 3 | (0.4) | 3 | (0.4) |
| 20A | 4 | (0.6) | 3 | (0.4) |
| 20B | 4 | (0.6) | 4 | (0.6) |
| 20D | 2 | (0.3) | 3 | (0.4) |
| 20H (Beta) | 5 | (0.7) | 6 | (0.9) |
| 20I (Alpha) | 17 | (2.4) | 10 | (1.4) |
| 20J (Gamma) | 37 | (5.2) | 50 | (7.2) |
| 21A (Delta) | 6 | (0.8) | 4 | (0.6) |
| 21G (Lambda) | 16 | (2.3) | 11 | (1.6) |
| 21H (Mu) | 83 | (11.7) | 92 | (13.2) |
| 21I (Delta) | 55 | (7.8) | 44 | (6.3) |
| 21J (Delta) | 298 | (42.0) | 295 | (42.2) |
| Unknownb | 4 | (0.6) | 4 | (0.6) |
| Unavailablec | 175 | (24.7) | 170 | (24.3) |
N number of participants for the corresponding category
aThe percentage is based on the number of participants in the modified intention-to-treat population
bThe sequence could not be classified (by Nextstrain) into a currently known clade
cNo evaluable sequence data were available. The predominant reasons for participants not having evaluable data were missing samples, poor sequence quality due to viral RNA titers that were too low or too high, or low sequence coverage